Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

For example, he proposed 25% tariffs on imports from Canada and Mexico ... is the main competition for Lilly's Mounjaro. Novo's obesity drug, Wegovy, is the top rival to Lilly's Zepbound.

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...